Uxía Couto-Lareo,Blanca Viejo-Sosa,Mònica Angerri-Nadal et al.
Uxía Couto-Lareo et al.
Introduction: Systemic lupus erythematosus is a heterogeneous autoimmune disease in which lupus nephritis represents one of the most severe and prognostically relevant manifestations, accounting for substantial morbidity ...
Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling [0.03%]
PD-1/PD-L1和CTLA-4在结直肠癌治疗中的靶向作用：肿瘤固有信号转导与免疫检查点信号转导
Sankha Bhattacharya
Sankha Bhattacharya
Introduction: Colorectal cancer (CRC) employs immune evasion strategies, particularly through the expression of immune checkpoint ligands, including PD-L1. These ligands interact with inhibitory receptors, including progr...
Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience - the APEX study [0.03%]
阿柏西普(艾叶亚希)(阿柏西普2mg生物类似药)治疗初治的视网膜血管性疾病：真实世界早期经验——APEX研究
Ashish Sharma,Alexander Shaer,Jingwen Zhang et al.
Ashish Sharma et al.
Purpose: To evaluate the early real-world efficacy of intravitreal aflibercept 2 mg biosimilar (aflibercept-ayyh, Pavblu, Amgen, USA.) across common retinal vascular diseases in treatment-naïve eyes. ...
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience [0.03%]
Tildrakizumab治疗中至重度斑块状银屑病：意大利真实世界经验的专家见解
Angelo Ruggiero,Martina Burlando,Anna Balato et al.
Angelo Ruggiero et al.
Introduction: Tildrakizumab, a selective interleukin (IL)-23 p19 inhibitor, is an established treatment for moderate-to-severe plaque psoriasis. However, clinical trials are characterized by strict eligibility criteria, w...
Emanuele Scala,Maria-Angeliki Gkini,Nina Magnolo et al.
Emanuele Scala et al.
Biologic therapies for axial spondyloarthritis: progress and future challenges [0.03%]
轴型脊柱关节炎的生物制剂治疗：进展与未来挑战
Daniel Wendling,Frank Verhœven,Clément Prati
Daniel Wendling
Personalized psoriatic arthritis therapy: the promise of chromosome conformation signatures [0.03%]
染色体构象特征标志物助力银屑病关节炎的个性化治疗
Patricia Riedlova,Carl S Goodyear,Stefan Siebert
Patricia Riedlova
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies [0.03%]
严重哮喘和鼻息肉慢性鼻窦炎的双重临床缓解：生物制剂治疗比较分析回顾
Carlo Lombardi,Francesco Menzella
Carlo Lombardi
Introduction: Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequent comorbidities driven by common Type 2 inflammatory pathways. While biologics target both conditions, a standardized definition...
Biologic therapies in Behçet's disease: current evidence, unmet needs, and future directions [0.03%]
贝赫切特病的生物制剂治疗：现有证据、未满足需求和未来方向
Nikolaos Kougkas
Nikolaos Kougkas
Advances in the management of giant cell arteritis-aortitis: biologic therapies and beyond - a narrative review [0.03%]
巨细胞动脉炎-主动脉炎的管理进展：生物制剂及其他——综述
Carmen Secada-Gómez,Adrián Martin-Gutiérrez,Javier Loricera et al.
Carmen Secada-Gómez et al.
Introduction: Giant cell arteritis (GCA) is the most common systemic vasculitis in individuals over 50 years of age. Aortic involvement is frequent, often clinically silent, and significantly increases the risk of thoraci...